Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis (EGPA): a European multicenter observational study.
Alessandra BettiolMaria Letizia UrbanLorenzo DagnaVincent CottinFranco FranceschiniStefano Del GiaccoFranco SchiavonThomas NeumannGiuseppe LopalcoPavel NovikovChiara BaldiniCarlo LombardiAlvise BertiFederico AlbericiMarco FolciSimone NegriniRenato Alberto SinicoLuca QuartuccioClaudio LunardiPaola ParronchiFrank MoosigGeorgina Espígol-FrigoléJan SchroederAnna Luise KernderSara MontiEttore SilvagniClaudia CrimiFrancesco CinettoPaolo FraticelliDario RoccatelloAngelo VaccaAladdin J MohammadBernhard HellmichMaxime SamsonElena BargagliJan Willem Cohen TervaertCamillo RibiDavide FioriFederica BelloFilippo FagniLuca MoroniGiuseppe Alvise RamirezMouhamad NasserChiara MarvisiPaola ToniatiDavide FirinuRoberto PadoanAllyson EganBenjamin SeeligerFlorenzo IannoneCarlo SalvaraniDavid JayneDomenico PriscoAugusto VaglioGiacomo Emminull nullPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2021)
Mepolizumab both at 100 and 300mg/4 weeks is effective for EGPA. The two dosages should be compared in the setting of a controlled trial.